COMPASS Pathways Q2 2024 Earnings Report $3.49 +0.08 (+2.35%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast COMPASS Pathways EPS ResultsActual EPS-$0.56Consensus EPS -$0.53Beat/MissMissed by -$0.03One Year Ago EPS-$0.62COMPASS Pathways Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACOMPASS Pathways Announcement DetailsQuarterQ2 2024Date8/1/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseCMPS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by COMPASS Pathways Earnings HeadlinesBrokerages Set COMPASS Pathways plc (NASDAQ:CMPS) Price Target at $33.60January 19 at 3:39 AM | americanbankingnews.comCompass Pathways to Participate in December Investor ConferencesNovember 25, 2024 | businesswire.comThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…January 21, 2025 | Crypto 101 Media (Ad)COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stakeNovember 25, 2024 | finance.yahoo.comCompass Pathways to participate in Stifel 2024 Healthcare ConferenceNovember 14, 2024 | globenewswire.comStrategic Opportunity in COMPASS Pathways Amid Extended Phase 3 Trials and Conservative Price TargetNovember 11, 2024 | markets.businessinsider.comSee More COMPASS Pathways Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like COMPASS Pathways? Sign up for Earnings360's daily newsletter to receive timely earnings updates on COMPASS Pathways and other key companies, straight to your email. Email Address About COMPASS PathwaysCOMPASS Pathways (NASDAQ:CMPS) operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.View COMPASS Pathways ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025)Abbott Laboratories (1/22/2025)Johnson & Johnson (1/22/2025)Procter & Gamble (1/22/2025)Travelers Companies (1/22/2025)Progressive (1/22/2025)GE Vernova (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
